CLINICAL_TRIALS
trial_result
· 2024-09-19
Clinical Trial Update: A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. [Phase 2]
Summary
Pfizer completed a Phase 2 study of elranatamab (PF-06863135) in Chinese participants with refractory/relapsed multiple myeloma, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Elranatamab, Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2024-09-19